Morepen Laboratories Secures INR 825 Cr  Global CDMO Deal

Supply under the agreement is expected to commence within the next 4–5 months, with execution scheduled through the first quarter of the following financial year, subject to standard operational and regulatory approvals.

Morepen Laboratories Limited has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs. 825 crore (USD 91 million) from a leading global pharmaceutical company. Supply under the agreement is expected to commence within the next 4–5 months, with execution scheduled through the first quarter of the following financial year, subject to standard operational and regulatory approvals.

The mandate represents one of the largest single CDMO engagements in Morepen’s history, signaling the company’s growing footprint in global manufacturing. With over four decades of expertise in active pharmaceutical ingredient (API) production, Morepen’s CDMO platform enables structured, multi-year collaborations with international pharmaceutical innovators.

The company’s capabilities span regulated markets, supported by facilities accredited by USFDA, WHO-GMP, and EU authorities. Integrated development-to-commercial manufacturing processes allow Morepen to manage complex scale-ups and long-duration supply programs. Plans for capacity enhancement and technology upgrades are underway to meet rising CDMO demand.

“This mandate represents an important milestone in the evolution of Morepen's manufacturing platform,” said Sushil Suri, Chairman and Managing Director. “It reflects global customer confidence in our quality systems, regulatory track record, and execution capabilities. CDMO is a natural extension of our API strengths, creating long-term scale and value while reinforcing our core business.”

Kushal Suri, President – International Growth (API), added, “This engagement demonstrates our ability to qualify, execute, and deliver under regulated-market expectations. The outcome validates Morepen’s credibility and positions us to convert this into larger, multi-year global opportunities.”

Global pharmaceutical firms are increasingly consolidating supplier networks and seeking reliable manufacturing platforms capable of consistent long-term supply. Morepen’s vertically integrated API capabilities, regulatory compliance, and operational scale align with this evolving market need.

Stay tuned for more such updates on Digital Health News